{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:34:43Z","timestamp":1777674883356,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NCI","award":["1UM1CA186709-01"],"award-info":[{"award-number":["1UM1CA186709-01"]}]},{"name":"NCI","award":["2UM1CA186691-06"],"award-info":[{"award-number":["2UM1CA186691-06"]}]},{"name":"NCI","award":["2UM1CA186691-06"],"award-info":[{"award-number":["2UM1CA186691-06"]}]},{"name":"NCI","award":["2UM1CA186691-06"],"award-info":[{"award-number":["2UM1CA186691-06"]}]},{"name":"NCI","award":["2UM1CA186691-06"],"award-info":[{"award-number":["2UM1CA186691-06"]}]},{"name":"NCI","award":["2UM1CA186691-06"],"award-info":[{"award-number":["2UM1CA186691-06"]}]},{"name":"NCI","award":["2UM1CA186691-06"],"award-info":[{"award-number":["2UM1CA186691-06"]}]},{"name":"NCI","award":["2UM1CA186691-06"],"award-info":[{"award-number":["2UM1CA186691-06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04760-1","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T09:39:30Z","timestamp":1740476370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1\/2 inhibitor, vistusertib, in patients with advanced solid tumors"],"prefix":"10.1007","volume":"95","author":[{"given":"Susan C.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Farago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Victoria","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Zahurak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Carducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Uziel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Takebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine L.","family":"Hann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"4760_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","volume":"11","author":"GF Perini","year":"2018","unstructured":"Perini GF, Ribeiro GN, Pinto Neto JV et al (2018) BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol 11:65","journal-title":"J Hematol Oncol"},{"key":"4760_CR2","unstructured":"FDA Label (PDF) Venetoclax"},{"key":"4760_CR3","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1158\/0008-5472.CAN-10-4336","volume":"71","author":"J Shi","year":"2011","unstructured":"Shi J, Zhou Y, Huang H-C, Mitchison TJ (2011) Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res 71:4518\u20134526","journal-title":"Cancer Res"},{"key":"4760_CR4","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1158\/0008-5472.CAN-06-3964","volume":"67","author":"S Chen","year":"2007","unstructured":"Chen S, Dai Y, Harada H et al (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing bak activation and Bax Translocation. Cancer Res 67:782\u2013791","journal-title":"Cancer Res"},{"key":"4760_CR5","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421\u20133428","journal-title":"Cancer Res"},{"key":"4760_CR6","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","volume":"14","author":"AR Shoemaker","year":"2008","unstructured":"Shoemaker AR, Mitten MJ, Adickes J et al (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14:3268\u20133277","journal-title":"Clin Cancer Res"},{"key":"4760_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/pbc.21433","volume":"50","author":"R Lock","year":"2008","unstructured":"Lock R, Carol H, Houghton PJ et al (2008) Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50:1181\u20131189","journal-title":"Pediatr Blood Cancer"},{"key":"4760_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/path.1711770206","volume":"177","author":"S-X Jiang","year":"1995","unstructured":"Jiang S-X, Sato Y, Kuwao S, Kameya T (1995) Expression ofbcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177:135\u2013138","journal-title":"J Pathol"},{"key":"4760_CR9","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1158\/0008-5472.CAN-07-5031","volume":"68","author":"CL Hann","year":"2008","unstructured":"Hann CL, Daniel VC, Sugar EA et al (2008) Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 68:2321\u20132328","journal-title":"Cancer Res"},{"key":"4760_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS et al (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11:1149\u20131159","journal-title":"Lancet Oncol"},{"key":"4760_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR et al (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488\u2013496","journal-title":"J Clin Oncol"},{"key":"4760_CR12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","volume":"29","author":"L Gandhi","year":"2011","unstructured":"Gandhi L, Ross Camidge D, de Oliveira MR et al (2011) Phase I study of Navitoclax (ABT-263), a Novel Bcl-2 family inhibitor, in patients with small-cell Lung Cancer and other solid tumors. J Clin Oncol 29:909\u2013916","journal-title":"J Clin Oncol"},{"key":"4760_CR13","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Hann CL, Garon EB et al (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18:3163\u20133169","journal-title":"Clin Cancer Res"},{"key":"4760_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"MF van Delft","year":"2006","unstructured":"van Delft MF, Wei AH, Mason KD et al (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell 10:389\u2013399","journal-title":"Cancer Cell"},{"key":"4760_CR15","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/0008-5472.CAN-13-3460","volume":"74","author":"EE Gardner","year":"2014","unstructured":"Gardner EE, Connis N, Poirier JT et al (2014) Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Res 74:2846\u20132856","journal-title":"Cancer Res"},{"key":"4760_CR16","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274\u2013293","journal-title":"Cell"},{"key":"4760_CR17","doi-asserted-by":"publisher","first-page":"10853","DOI":"10.1073\/pnas.0804821105","volume":"105","author":"JR Mills","year":"2008","unstructured":"Mills JR, Hippo Y, Robert F et al (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A 105:10853\u201310858","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4760_CR18","doi-asserted-by":"crossref","unstructured":"Tian T, Li X, Zhang J (2019) mTOR Signaling in Cancer and mTOR inhibitors in solid Tumor Targeting Therapy. Int J Mol Sci 20","DOI":"10.3390\/ijms20030755"},{"key":"4760_CR19","doi-asserted-by":"publisher","first-page":"E1288","DOI":"10.1073\/pnas.1411848112","volume":"112","author":"AC Faber","year":"2015","unstructured":"Faber AC, Farago AF, Costa C et al (2015) Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A 112:E1288\u2013E1296","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4760_CR20","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1158\/1078-0432.CCR-14-2422","volume":"21","author":"B Basu","year":"2015","unstructured":"Basu B, Dean E, Puglisi M et al (2015) First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1\/2 inhibitor AZD2014. Clin Cancer Res 21:3412\u20133419","journal-title":"Clin Cancer Res"},{"key":"4760_CR21","doi-asserted-by":"crossref","unstructured":"Jordan JT, Orr CC, Thalheimer RD et al (2023) Prospective phase 2 trial of the dual mTORC1\/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2. Neuro Oncol Adv vdad041","DOI":"10.1093\/noajnl\/vdad041"},{"key":"4760_CR22","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/annonc\/mdy245","volume":"29","author":"B Basu","year":"2018","unstructured":"Basu B, Krebs MG, Sundar R et al (2018) Vistusertib (dual m-TORC1\/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann Oncol 29:1918\u20131925","journal-title":"Ann Oncol"},{"key":"4760_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7966","author":"S Banerjee","year":"2023","unstructured":"Banerjee S, Giannone G, Clamp AR et al (2023) Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel alone in patients with platinum-resistant ovarian high-Grade Serous Carcinoma: the OCTOPUS Multicenter, phase 2, Randomized Clinical Trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7966","journal-title":"JAMA Oncol"},{"key":"4760_CR24","doi-asserted-by":"crossref","unstructured":"Scott SC, Anders NM, He P et al (2021) Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclax. Biomed Chromatogr e5289","DOI":"10.1002\/bmc.5383"},{"key":"4760_CR25","doi-asserted-by":"publisher","first-page":"114436","DOI":"10.1016\/j.jpba.2021.114436","volume":"208","author":"SC Scott","year":"2022","unstructured":"Scott SC, Anders NM, Scardina M et al (2022) Validation of a rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of vistusertib. J Pharm Biomed Anal 208:114436","journal-title":"J Pharm Biomed Anal"},{"key":"4760_CR26","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00280-015-2883-8","volume":"76","author":"AW Tolcher","year":"2015","unstructured":"Tolcher AW, LoRusso P, Arzt J et al (2015) Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 76:1025\u20131032","journal-title":"Cancer Chemother Pharmacol"},{"key":"4760_CR27","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bjh.13487","volume":"170","author":"AW Roberts","year":"2015","unstructured":"Roberts AW, Advani RH, Kahl BS et al (2015) Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20\u2009+\u2009lymphoid malignancies. Br J Haematol 170:669\u2013678","journal-title":"Br J Haematol"},{"key":"4760_CR28","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1080\/10428194.2021.1938027","volume":"62","author":"GP Collins","year":"2021","unstructured":"Collins GP, Clevenger TN, Burke KA et al (2021) A phase 1\/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed\/refractory B-cell malignancies. Leuk Lymphoma 62:2625\u20132636","journal-title":"Leuk Lymphoma"},{"key":"4760_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10637-014-0110-9","volume":"32","author":"JM Cleary","year":"2014","unstructured":"Cleary JM, Lima CMSR, Hurwitz HI et al (2014) A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs 32:937\u2013945","journal-title":"Invest New Drugs"},{"key":"4760_CR30","doi-asserted-by":"publisher","first-page":"105458","DOI":"10.1016\/j.isci.2022.105458","volume":"25","author":"MC McNamara","year":"2022","unstructured":"McNamara MC, Hosios AM, Torrence ME et al (2022) Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex. iScience 25:105458","journal-title":"iScience"},{"key":"4760_CR31","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1158\/1078-0432.CCR-22-2729","volume":"29","author":"T Satta","year":"2023","unstructured":"Satta T, Li L, Chalasani SL et al (2023) Dual mTORC1\/2 inhibition synergistically enhances AML cell death in combination with the BCL2 antagonist venetoclax. Clin Cancer Res 29:1332\u20131343","journal-title":"Clin Cancer Res"},{"key":"4760_CR32","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.7150\/jca.29192","volume":"10","author":"AH Nayman","year":"2019","unstructured":"Nayman AH, Siginc H, Zemheri E et al (2019) Dual-inhibition of mTOR and Bcl-2 enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma in Vitro and in vivo. J Cancer 10:1466\u20131478","journal-title":"J Cancer"},{"key":"4760_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","volume":"19","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA et al (2019) Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer 19:289\u2013297","journal-title":"Nat Rev Cancer"},{"key":"4760_CR34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM et al (2021) Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39:346\u2013360e7","journal-title":"Cancer Cell"},{"key":"4760_CR35","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1152\/physiolgenomics.00173.2013","volume":"46","author":"P Vachhani","year":"2014","unstructured":"Vachhani P, Bose P, Rahmani M, Grant S (2014) Rational combination of dual PI3K\/mTOR blockade and Bcl-2\/-xL inhibition in AML. Physiol Genomics 46:448\u2013456","journal-title":"Physiol Genomics"},{"key":"4760_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1158\/2159-8290.CD-13-0315","volume":"4","author":"AC Faber","year":"2014","unstructured":"Faber AC, Coffee EM, Costa C et al (2014) mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2\/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 4:42\u201352","journal-title":"Cancer Discov"},{"key":"4760_CR37","doi-asserted-by":"publisher","first-page":"e14653","DOI":"10.1200\/JCO.2019.37.15_suppl.e14653","volume":"37","author":"S Sammons","year":"2019","unstructured":"Sammons S, Anderson G, Wardell S et al (2019) Combination mTORC1\/2 and BCL- XL inhibition in endocrine and CDK4\/6-resistant estrogen receptor-positive breast cancer. J Clin Oncol 37:e14653\u2013e14653","journal-title":"J Clin Oncol"},{"key":"4760_CR38","doi-asserted-by":"publisher","first-page":"369ra175","DOI":"10.1126\/scitranslmed.aae0348","volume":"8","author":"GR Anderson","year":"2016","unstructured":"Anderson GR, Wardell SE, Cakir M et al (2016) PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Sci Transl Med 8:369ra175","journal-title":"Sci Transl Med"},{"key":"4760_CR39","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/s41375-020-01080-6","volume":"35","author":"A Emadi","year":"2021","unstructured":"Emadi A, Kapadia B, Bollino D et al (2021) Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia. Leukemia 35:1907\u20131924","journal-title":"Leukemia"},{"key":"4760_CR40","doi-asserted-by":"crossref","unstructured":"Liu Y, Bollino DR, Bah OM et al (2024) A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed\/refractory acute myeloid leukemia. Blood blood.2024024837","DOI":"10.1182\/blood.2024024837"},{"key":"4760_CR41","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/s41416-020-01041-x","volume":"123","author":"MH Voss","year":"2020","unstructured":"Voss MH, Gordon MS, Mita M et al (2020) Phase 1 study of mTORC1\/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. Br J Cancer 123:1590\u20131598","journal-title":"Br J Cancer"},{"key":"4760_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41698-023-00369-w","volume":"7","author":"O Alhalabi","year":"2023","unstructured":"Alhalabi O, Groisberg R, Zinner R et al (2023) Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7:37","journal-title":"NPJ Precis Oncol"},{"key":"4760_CR43","doi-asserted-by":"publisher","first-page":"102123","DOI":"10.1016\/j.clgc.2024.102123","volume":"22","author":"J Bellmunt","year":"2024","unstructured":"Bellmunt J, Maroto P, Bonfill T et al (2024) Dual mTOR1\/2 inhibitor sapanisertib (FTH-003\/TAK-228) in combination with weekly paclitaxel in patients with previously treated metastatic urothelial carcinoma: a phase II open-label study. Clin Genitourin Cancer 22:102123","journal-title":"Clin Genitourin Cancer"},{"key":"4760_CR44","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/1078-0432.CCR-23-1525","volume":"30","author":"NJ Lakhani","year":"2024","unstructured":"Lakhani NJ, Rasco D, Wang H et al (2024) First-in-human study with preclinical data of BCL-2\/BCL-xL inhibitor pelcitoclax in locally advanced or metastatic solid tumors. Clin Cancer Res 30:506\u2013521","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04760-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04760-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04760-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T09:39:36Z","timestamp":1740476376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04760-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4760"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04760-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SCS receives research funding direct to institution from Janssen, Mirati Therapeutics, and Black Diamond Therapeutics and has consulting relationships with AstraZeneca, Daiichi-Sankyo, Genentech, Janssen, Merus, and Regeneron. AFF is a current employee of Amgen and has stock ownership in Amgen and Novartis. WVL is a current employee of AstraZeneca and currently has stock ownership with AstraZeneca. TA is a current employee of AbbVie and may own stocks. CMR has consulted regarding oncology drug development with AbbVie, Amgen, AstraZeneca, Jazz, Mariana and Scorpion Therapeutics, and serves on the scientific advisory boards of Auron, DISCO, Earli, and Harpoon Therapeutics. CLH reports research funding direct to institution from AbbVIe, Amgen, AstraZeneca, Daiichi Sankyo and has a consulting relationship with AbbVie, Amgen, and AstraZeneca and serves on the scientific advisory boards of AstraZeneca and Daiichi Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}